Definium Therapeutics, Inc. - Asset Resilience Ratio
Definium Therapeutics, Inc. (DFTX) has an Asset Resilience Ratio of 34.94% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read DFTX current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Definium Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. See what is Definium Therapeutics, Inc.'s book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Definium Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see DFTX company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $153.76 Million | 34.94% |
| Total Liquid Assets | $153.76 Million | 34.94% |
Asset Resilience Insights
- Very High Liquidity: Definium Therapeutics, Inc. maintains exceptional liquid asset reserves at 34.94% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Definium Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Definium Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Definium Therapeutics, Inc. (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Definium Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 34.94% | $153.76 Million | $440.10 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $302.15 Million | -- |
| 2017-12-31 | 41.88% | $1.69 Million | $4.03 Million | -- |
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a cli… Read more